American Academy of Allergy, Asthma & Immunology. Allergy statistics. Available at: http://www.aaaai.org/about-the-aaaai/newsroom/allergy-statistics.aspx. Accessed July 8, 2014.
Centers For Disease Control and Prevention. Allergies and hay fever. Available at: http://www.cdc.gov/nchs/fastats/allergies.htm. Accessed July 8, 2014.
Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127:S1-S55. Abstract
Cox LS, Casale TB, Nayak AS, et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. J Allergy Clin Immunol. 2012;130:1327-1334. Abstract
Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol. 2011;127:64-71. Abstract
Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011;127:72-80. Abstract
Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large, randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112:146-153. Abstract
Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults. J Allergy Clin Immunol. 2013;131:1342-1349. Abstract
Creticos PS, Esch RE, Couroux P, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014;133:751-758. Abstract
Nolte H, Hébert J, Berman G, et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol. 2013;110:450-456. Abstract
Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717-725. Abstract
Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract. 2014;2:161-167. Abstract
Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol. 2010;125:569-574. Abstract
Pollart SM, Reid MJ, Fling JA, Chapman MD, Platts-Mills TA. Epidemiology of emergency room asthma in northern California: association with IgE antibody to ryegrass pollen. J Allergy Clin Immunol. 1988;82:224-230. Abstract
Calderón MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67:302-311. Abstract
Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol. 2009;103:451-459. Abstract
Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7:6.
Cox LS, Hankin C, Lockey R. Allergen immunotherapy adherence and delivery route: Locations does not matter. J Allergy Clin Immunol Pract. 2014;2:156-160. Abstract
Pajno GB, Vita D, Caminiti L, et al. Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol. 2005;116:1380-1381. Abstract
Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol. 2012;2:280-284. Abstract
Sieber J, De Geest S, Shah-Hosseini K, Mösges R. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin. 2011;27:855-861. Abstract
Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132:353-360. Abstract
DuBuske LM, Frew AJ, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc. 2011;32:239-247. Abstract
Patel P, Holdich T, Fischer von Weikersthal-Drachenberg KJ, Huber B. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen. J Allergy Clin Immunol. 2014;133(1):121-129.
Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355:1445-1455. Abstract
Norman PS, Ohman JL Jr, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med. 1996;154:1623-1628. Abstract
Naclerio RM, Proud D, Moylan B, et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol. 1997;100:293-300. Abstract

CME

Clinical Developments in Allergen Immunotherapy

Authors: Michael R. Nelson, MD, PhD, COL; Linda S. Cox, MD; Peter S. Creticos, MD; Tolly Epstein, MD, MS
CME Released: 7/23/2014
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 7/23/2015

Target Audience and Goal Statement

This activity is intended for allergists and other clinicians who provide care for patients with allergic diseases

The goal of this activity is to provide education on the use of allergen immunotherapy for patients with allergic diseases

Upon completion of this activity, participants will be able to:

Identify clinical implications of recent advances in allergen immunotherapy
Summarize the safety and efficacy of recently approved allergen immunotherapies
Distinguish between subcutaneous and sublingual immunotherapy options with respect to potential benefits and limitations

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator(s)

Michael R. Nelson, MD, PhD, COL

Director for Education, Training, and Research, Walter Reed National Military Medical Center, Bethesda, Maryland

Disclosures

Disclosure: Michael R. Nelson, MD, PhD, COL, has disclosed no relevant financial relationships.

Dr Nelson does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Nelson does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

Linda S. Cox, MD

Associate Clinical Professor, Department of Medicine, Nova Southeastern University, Davie, Florida

Disclosures

Disclosure: Linda S. Cox, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Greer
Served on the adjudication committee for: Medimmune Inc.; Novartis Pharmaceuticals Corporation
Served on the Data Safety Monitoring Committee for: Circassia, Ltd.

Dr Cox does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Cox does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Peter S. Creticos, MD

Associate Professor of Medicine, Department of Medicine, Johns Hopkins University School of Medicine; Johns Hopkins Asthma & Allergy Center, Baltimore, Maryland; Director, of Clinical Research, Creticos Research Group, LLC, Crownsville, Maryland

Disclosures

Disclosure: Participation by Dr Creticos as a member of the Scientific Advisory Board does not constitute or imply endorsement by The Johns Hopkins University or the Johns Hopkins Hospital and Health System. Peter S. Creticos, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consult for: Circassia, Ltd.; Greer
Received grants for clinical research from: Circassia, Ltd.; Greer; Merck & Co., Inc.

Dr Creticos does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Creticos does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Tolly Epstein, MD, MS

Assistant Professor of Clinical Medicine, University of Cincinnati, Cincinnati, Ohio

Disclosures

Disclosure: Tolly Epstein, MD, MS, has disclosed the following relevant financial relationships:
Received grants for clinical research from: Teva Pharmaceuticals USA

Dr Epstein does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Epstein does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor(s)

Sarah Williams, PhD

Senior Scientific Director, Medscape, LLC

Disclosures

Disclosure: Sarah Williams, PhD, has disclosed no relevant financial relationships.

Steering Committee

Linda S. Cox, MD

Disclosures

As listed above.

Tolly Epstein, MD, MS

Disclosures

As listed above.

Mark S. Dykewicz, MD

Raymond and Alberta Slavin Endowed Chair in Allergy & Immunology; Professor of Internal Medicine; Chief, Allergy & Immunology, Saint Louis University School of Medicine, St. Louis, Missouri

Disclosures

Disclosure: Mark S. Dykewicz, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consult for: Merck & Co., Inc.
Received grants for clinical research from: Novartis Pharmaceuticals Corporation

Peter S. Creticos, MD

Disclosures

As listed above.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Allergy & Clinical Immunology

CME

Clinical Developments in Allergen Immunotherapy

Authors: Michael R. Nelson, MD, PhD, COL; Linda S. Cox, MD; Peter S. Creticos, MD; Tolly Epstein, MD, MSFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CME Released: 7/23/2014

Valid for credit through: 7/23/2015

processing....

This feature requires the newest version of Flash. You can download it here.

CME Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator(s)

Michael R. Nelson, MD, PhD, COL

Panelist(s)

Linda S. Cox, MD

Peter S. Creticos, MD

Tolly Epstein, MD, MS

Editor(s)

Sarah Williams, PhD

Steering Committee

Linda S. Cox, MD

Tolly Epstein, MD, MS

Mark S. Dykewicz, MD

Peter S. Creticos, MD

CME Reviewer(s)

Nafeez Zawahir, MD

CME

Clinical Developments in Allergen Immunotherapy

Target Audience and Goal Statement

Disclosures

Moderator(s)

Michael R. Nelson, MD, PhD, COL

Panelist(s)

Linda S. Cox, MD

Peter S. Creticos, MD

Tolly Epstein, MD, MS

Editor(s)

Sarah Williams, PhD

Steering Committee

Linda S. Cox, MD

Tolly Epstein, MD, MS

Mark S. Dykewicz, MD

Peter S. Creticos, MD

CME Reviewer(s)

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Clinical Developments in Allergen Immunotherapy